Iqvia Holdings Inc. IQV
We take great care to ensure that the data presented and summarized in this overview for IQVIA HOLDINGS INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding IQV
View all-
Vanguard Group Inc Valley Forge, PA20MShares$3.89 Billion0.09% of portfolio
-
Black Rock Inc. New York, NY15.2MShares$2.96 Billion0.07% of portfolio
-
State Street Corp Boston, MA7.76MShares$1.51 Billion0.08% of portfolio
-
Geode Capital Management, LLC Boston, MA4.1MShares$796 Million0.08% of portfolio
-
Alliancebernstein L.P. New York, NY3.89MShares$757 Million0.32% of portfolio
-
Morgan Stanley New York, NY3.79MShares$737 Million0.07% of portfolio
-
Canada Pension Plan Investment Board Toronto Ontario, A63.57MShares$694 Million0.86% of portfolio
-
Lazard Asset Management LLC New York, NY3.33MShares$648 Million1.16% of portfolio
-
Farallon Capital Management LLC San Francisco, CA3.17MShares$616 Million3.78% of portfolio
-
Mitsubishi Ufj Kokusai Asset Management Co., Ltd.2.38MShares$462 Million0.61% of portfolio
Latest Institutional Activity in IQV
Top Purchases
Top Sells
About IQV
IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with HealthCore, Inc. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.
Insider Transactions at IQV
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Aug 27
2024
|
Eric Sherbet Officer |
SELL
Open market or private sale
|
Direct |
1,300
-6.24%
|
$319,800
$246.33 P/Share
|
Jul 28
2024
|
Keriann Cherofsky Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
35
-4.44%
|
$8,365
$239.67 P/Share
|
Jul 28
2024
|
Bhavik Patel Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
83
-13.22%
|
$19,837
$239.67 P/Share
|
May 07
2024
|
Colleen A Goggins Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,047
+8.49%
|
-
|
May 07
2024
|
John Connaughton Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,047
+50.0%
|
-
|
May 07
2024
|
John M Leonard Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,047
+7.06%
|
-
|
May 07
2024
|
John G Danhakl Director |
BUY
Grant, award, or other acquisition
|
Indirect |
1,047
+3.67%
|
-
|
Mar 01
2024
|
Ari Bousbib Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
11,169
-1.4%
|
$2,781,081
$249.97 P/Share
|
Mar 01
2024
|
Ari Bousbib Director |
SELL
Open market or private sale
|
Direct |
31,678
-1.93%
|
$7,919,500
$250.54 P/Share
|
Mar 01
2024
|
Ari Bousbib Director |
BUY
Exercise of conversion of derivative security
|
Direct |
42,847
+4.92%
|
$2,785,055
$65.16 P/Share
|
Feb 29
2024
|
W Richard Staub Officer |
SELL
Open market or private sale
|
Direct |
14,100
-18.62%
|
$3,496,800
$248.25 P/Share
|
Feb 28
2024
|
Kevin C Knightly Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
4,599
-87.58%
|
$1,154,349
$251.02 P/Share
|
Feb 28
2024
|
Kevin C Knightly Officer |
SELL
Open market or private sale
|
Direct |
8,607
-37.86%
|
$2,151,750
$250.39 P/Share
|
Feb 28
2024
|
Kevin C Knightly Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,206
+40.71%
|
$1,135,716
$86.72 P/Share
|
Feb 16
2024
|
Eric Sherbet Officer |
SELL
Open market or private sale
|
Direct |
1,000
-4.58%
|
$241,000
$241.5 P/Share
|
Feb 16
2024
|
Kevin C Knightly Officer |
SELL
Open market or private sale
|
Direct |
13,468
-39.64%
|
$3,245,788
$241.01 P/Share
|
Feb 16
2024
|
Kevin C Knightly Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
3,941
-40.0%
|
$949,781
$241.14 P/Share
|
Feb 16
2024
|
Kevin C Knightly Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,149
+40.22%
|
$947,622
$78.21 P/Share
|
Feb 10
2024
|
Kevin C Knightly Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
303
-4.88%
|
$66,054
$218.2 P/Share
|
Feb 10
2024
|
Eric Sherbet Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
289
-1.31%
|
$63,002
$218.2 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 139K shares |
---|---|
Exercise of conversion of derivative security | 86.7K shares |
Sale (or disposition) back to the issuer | 25.1K shares |
---|---|
Payment of exercise price or tax liability | 73.5K shares |
Open market or private sale | 83.3K shares |